A promising cell-therapy approach for heart failure aims at differentiating human pluripotent
stem cells (hPSCs) into functional cardiomyocytes (CMs) in vitro to replace the disease …

Heart disease is one of the major life-threatening diseases with high mortality and incidence
worldwide. Several model systems, such as primary cells and animals, have been used to …

Cardiomyocytes (CMs), endothelial cells (ECs), smooth-muscle cells (SMCs), and cardiac
fibroblasts (CFs) differentiated from human induced-pluripotent stem cells (hiPSCs) are the …

Human iPSC-derived cardiomyocytes (hiPSC-CMs) have proven invaluable for cardiac
disease modeling and regeneration. Challenges with quality, inter-batch consistency …

Patients with chronic heart failure (HF) have a poor prognosis due to irreversible impairment
of left ventricular function, with 5-year survival rates< 60%. Despite advances in …

Cardiovascular diseases are the leading cause of death worldwide. Several strategies–
small molecules, gene therapy, surgeries, cardiac rehabilitation–have been developed to …

In this study, we used machine learning (ML) to classify the cardiomyocyte (CM) content on
day 10 of the differentiation of human-induced pluripotent stem cell (hiPSC)-laden …

For β-cell replacement therapies, one challenge is the manufacturing of enough β-cells
(Edmonton protocol for islet transplantation requires 0.5–1× 106 islet equivalents). To …

Background Commonly used media for the differentiation of human pluripotent stem cells
into cardiomyocytes (hPSC-CMs) contain high concentrations of proteins, in particular …

A transformation is underway in precision and patient‐specific medicine. Rapid progress
has been enabled by multiple new technologies including induced pluripotent stem cell …